Abstract

Memory consolidation underpins adaptive behavior and dopaminergic networks may be critical for prolonged, selective information storage. To understand the time course of the dopaminergic contribution to memory consolidation in humans, here we investigate the effect of dopaminergic medication on recall and recognition in the short and longer term in Parkinson disease (PD). Fifteen people with PD were each tested on or off dopaminergic medication during learning/early consolidation (Day 1) and/or late consolidation (Day 2). Fifteen age-matched healthy participants were tested only once. On Day 1 participants learned new information, and early episodic memory was tested after 30 min. Then on Day 2, recall and recognition were retested after a 24-hr delay. Participants on medication on Day 1 recalled less information at 30 min and 24 hr. In contrast, patients on medication on Day 2 (8-24 hr after learning) recalled more information at 24 hr than those off medication. Although recognition sensitivity was unaffected by medication, response bias was dependent on dopaminergic state: Medication during learning induced a more liberal bias 24 hr later, whereas patients off medication during learning were more conservative responders 24 hr later. We use computational modeling to propose possible mechanisms for this change in response bias. In summary, dopaminergic medication in PD patients during learning impairs early consolidation of episodic memory and makes delayed responses more liberal, but enhances late memory consolidation presumably through a dopamine-dependent consolidation pathway that may be active during sleep.

Highlights

  • Memory impairment in neurodegenerative disease has often been considered to be explained by loss of cholinergic neurons (e.g., Bartus, Dean, Beer, & Lippa, 1982)

  • The response bias effects were the most unexpected results we found, and we were unable to come up with a simple explanation, so we turned to computational models of familiarity discrimination to see if an interaction of delay and Day 1 medication state could be found in the models

  • We investigated the effect of dopaminergic medication on memory consolidation in Parkinson disease (PD) patients tested on and off dopaminergic medications during learning/early consolidation and late consolidation/recall

Read more

Summary

Introduction

Memory impairment in neurodegenerative disease has often been considered to be explained by loss of cholinergic neurons (e.g., Bartus, Dean, Beer, & Lippa, 1982). Dopamine antagonist infusion during or immediately after encoding worsens delayed recall in animals (Bethus, Tse, & Morris, 2010; O’Carroll, Martin, Sandin, Frenguelli, & Morris, 2006), suggesting a benefit of dopaminergic activity on encoding and perhaps early consolidation. This is supported by a recent observation that optogenetic stimulation of dopaminergic neurons during learning enhances memory retention (McNamara, TejeroCantero, Trouche, Campo-Urriza, & Dupret, 2014). The authors suggested that dopaminergic input to the CA1 increases the reactivation of newly formed neuronal assemblies to allow for consolidation of the memories they encode

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call